Aptevo Therapeutics Announces CEO Transition: Lamothe to Lead, White to Executive Chair
APVO is trading near its 52-week low of $6.88 (5.5% above the low).
Summary
Aptevo Therapeutics announced a leadership transition, with current CEO Marvin L. White moving to Executive Chair and COO Jeff Lamothe being promoted to President and CEO, effective April 1, 2026.
Key Events · Executive and Board Changes · APVO
-
CEO Transition Announced
Marvin L. White will retire as President and Chief Executive Officer, effective April 1, 2026, and transition to the role of Executive Chair of the Board.
-
New CEO Appointed
Jeff Lamothe, currently Chief Operating Officer, will assume the role of President and Chief Executive Officer and join the Board of Directors, effective April 1, 2026.
-
Board Leadership Change
John E. Niederhuber, M.D., will transition from Chairman of the Board to Lead Independent Director, effective April 1, 2026.
-
Executive Compensation Details
New CEO Jeff Lamothe will receive an annual base salary of $650,000, an annual bonus target of 60% of his base salary, and a one-time promotional award of $150,000. Marvin White's annual base salary as Executive Chair will be $275,000 with no bonus eligibility.
Analysis · APVO · Life Sciences
This filing details a significant leadership transition at Aptevo Therapeutics, with current CEO Marvin L. White moving to Executive Chair and COO Jeff Lamothe stepping into the CEO role. For a clinical-stage biotechnology company, especially one with a small market capitalization and recent substantial financing activities, leadership stability and strategic direction are critical. The internal promotion of Mr. Lamothe, who has a long history with the company, and Mr. White's continued involvement as Executive Chair, suggest a planned and orderly transition aimed at maintaining continuity and focusing on long-term growth. This move provides clarity on the company's future leadership as it navigates clinical development and capital deployment.
At the time of this filing, APVO was trading at $7.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $6.88 to $1,616.47. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.